ALS, also known as Lou Gehrig's disease, is a late-onset neurodegenerative disease characterized by loss of motor neurons, progressive weakness and eventual paralysis and death within 3-5 years of diganosis 1 . Most ALS cases are sporadic (SALS), but 10% are familial (FALS), of which ~20% result from mutations in the SOD1 gene (encoding Cu/Zn superoxide dismutase 1) 2 . SOD1 mutations are thought to cause disease by a toxic gain of function 3 , and, thus, strategies to lower SOD1 levels are being pursued 4 . However, SOD1 mutations account for only a small percentage of ALS cases, and additional therapeutic strategies are needed.
ALS, also known as Lou Gehrig's disease, is a late-onset neurodegenerative disease characterized by loss of motor neurons, progressive weakness and eventual paralysis and death within 3-5 years of diganosis 1 . Most ALS cases are sporadic (SALS), but 10% are familial (FALS), of which ~20% result from mutations in the SOD1 gene (encoding Cu/Zn superoxide dismutase 1) 2 . SOD1 mutations are thought to cause disease by a toxic gain of function 3 , and, thus, strategies to lower SOD1 levels are being pursued 4 . However, SOD1 mutations account for only a small percentage of ALS cases, and additional therapeutic strategies are needed.
RNA-binding proteins and RNA-processing pathways have recently been implicated in ALS 5, 6 . The RNA-binding protein TDP-43 has been found in cytoplasmic inclusions in the spinal cord neurons of most ALS cases without SOD1 mutation 7, 8 , and mutations in TARDBP, which encodes TDP-43, have been identified in FALS and SALS cases [9] [10] [11] [12] [13] . Mutations in FUS, which encodes another RNA-binding protein (FUS, also called TLS), have also been found in some ALS cases [14] [15] [16] [17] [18] . Therefore, therapies targeting TDP-43 and/or FUS could be effective in cases not caused by SOD1 mutation. Notably, TDP-43 inclusions occur in many frontotemporal dementia cases, and targeting TDP-43 might be an effective therapeutic strategy for these patients. Efforts are under way to define the mechanisms by which TDP-43 and FUS and defects in RNA processing pathways contribute to ALS.
We have used yeast models to illuminate mechanisms underpinning TDP-43 and FUS aggregation and cellular toxicity [19] [20] [21] . TDP-43 forms aggregates in the cytoplasm of yeast cells and is toxic, recapitulating two key features of TDP-43 relevant to human disease 19 . We used a genome-wide plasmid overexpression screen to identify modifiers of aggregation and toxicity. One modifier of toxicity was Pbp1, whose human homolog, ataxin 2, harbors a polyglutamine tract that is expanded (>34 glutamines) in spinocerebellar ataxia type 2. We found that intermediate-length polyglutamine expansions (~27-33 glutamines) in ataxin 2 are a genetic risk factor for ALS 22, 23 . Additional genetic modifiers of TDP-43 toxicity in yeast might provide further insight into pathogenic mechanisms and could represent novel therapeutic targets.
Here, we report results from a genome-wide loss-of-function screen to identify yeast genes that modify TDP-43 toxicity. In our previous screen (ref. 22 and A.D.G., unpublished data), we used a library of yeast overexpression plasmids. Here, we interrogated collections of nonessential yeast knockouts and knockdowns of essential genes. Loss-of-function screens may be useful to identify therapeutic targets for which inhibitors could be developed. Among the most potent knockout suppressors of TDP-43 toxicity discovered in our screen was dbr1∆. Dbr1 catalyzes the debranching of lariat introns that are formed during pre-mRNA splicing. We show that inhibiting the debranching enzymatic activity of Dbr1 is sufficient to rescue TDP-43 toxicity. We also provide evidence that intronic lariat species that accumulate in the cytoplasm of dbr1∆ cells act as decoys to sequester toxic cytoplasmic TDP-43, possibly preventing it from interfering with other essential cellular RNA targets and RNA-binding proteins. Knockdown of Dbr1 in a human neuronal cell line and in primary rat neurons is also sufficient to rescue TDP-43 toxicity, suggesting that the effect of Dbr1 on TDP-43 toxicity is conserved from yeast to mammals. We propose that the debranching enzymatic activity of Dbr1 could be a potential therapeutic target for ALS and related TDP-43 proteinopathies.
RESULTS

DBR1 is a potent modifier of TDP-43 toxicity in yeast
To identify genes that modify TDP-43 toxicity, we performed two independent, unbiased genome-wide yeast deletion screens in two different laboratories (Supplementary Fig. 1 ). Similar approaches have been used to discover modifiers of the neurodegenerative disease proteins α-synuclein, huntingtin and FUS 21, 24, 25 . In the first screen, we used synthetic genetic array (SGA) analysis 26 to introduce a galactose-inducible plasmid expressing TDP-43 into each nonessential yeast deletion strain by mating (Supplementary Fig. 1a ). The second screen included the deletion genes and a library of essential genes generated by decreased abundance by mRNA perturbation (DAmP) technology 27 ( Supplementary Fig. 1b-e) . We selected yeast deletion strains in which TDP-43 was more (enhancer) or less (suppressor) toxic than in wild-type cells. Screen 1 was repeated three independent times, and only gene deletions that were reproduced all three times were selected. Screen 2 contained three biological and two technical replicates (six replicates in total), which allowed the calculation of an interaction score (a quantitative assessment of the effectiveness of suppression or enhancement of TDP-43 toxicity). To provide independent evidence that the gene deletions identified from the screens modify TDP-43 toxicity, we generated gene deletions for the hits from screen 1 and selected genes from screen 2 in an independent strain background, confirming the effects on TDP-43 toxicity. In screen 1, we identified 14 yeast deletion strains that modified TDP-43 toxicity (Table 1) : 6 enhancers and 8 suppressors. The more sensitive and quantitative analysis in screen 2 allowed us to identify a total of 2,581 potential enhancers and 2,056 potential suppressors (Supplementary Data). In analyzing these results, we chose to focus on suppressors of TDP-43 toxicity because these could represent attractive therapeutic targets for small molecule inhibitors or RNA interference (see the Supplementary Note for discussion of additional yeast TDP-43 toxicity modifier genes).
One of the most effective deletion suppressors of TDP-43 toxicity identified independently in both screens was dbr1∆, and we focused further efforts on the DBR1 gene. DBR1 deletion suppressed the toxicity of wild-type TDP-43, as well as that of an ALS-linked mutant form of TDP-43 (Gln331Lys; Fig. 1a and Supplementary Fig. 2 ). Immunoblotting confirmed that toxicity was not suppressed because of lower TDP-43 expression in the dbr1∆ strain (Fig. 1b) . Deletion of DBR1 did not suppress the toxicity of two other neurodegenerative disease proteins, α-synuclein and mutant huntingtin. Indeed, α-synuclein toxicity was slightly enhanced in the dbr1∆ strain (Fig. 1a) . However, DBR1 deletion suppressed toxicity of another RNA-binding protein linked to ALS, FUS (Fig. 1a) , showing specificity of the DBR1 genetic interaction for ALS-linked RNA-binding proteins TDP-43 and FUS.
Inhibiting DBR1 suppresses TDP-43 toxicity in mammalian cells
Identification of Dbr1 as a potent modifier of TDP-43 toxicity suggests the possibility that inhibiting Dbr1 enzymatic activity (Fig. 1c) could be a promising therapeutic strategy for ALS, especially as TDP-43 is thought to contribute broadly to almost all ALS cases without SOD1 mutation 7 . Therefore, we tested whether inhibiting Dbr1 function could rescue TDP-43 toxicity in mammalian cells. We generated a stable human M17 neuroblastoma cell line that inducibly expresses epitope-tagged ALS-linked mutant TDP-43 (Gln331Lys) under the control of a doxycycline-regulated promoter (Fig. 2a) . Inducible expression of TDP-43 Gln331Lys was confirmed by immunofluorescence and immunoblotting ( Fig. 2b and data not shown). Upregulating mutant TDP-43 was toxic in these cells (Fig. 2c) . To determine whether inhibiting Dbr1 rescues TDP-43 toxicity, we transfected these cell lines with a small interfering RNA (siRNA) against human DBR1 or a non-targeting control siRNA (Fig. 2d) . Neither siRNA affected TDP-43 expression in these cells (data not shown). Whereas the non-targeting siRNA had A r t i c l e s npg A r t i c l e s no effect on toxicity, transfection with the DBR1-specific siRNA significantly reduced TDP-43 toxicity (Fig. 2d) .
Inhibiting Dbr1 suppresses TDP-43 toxicity in primary neurons
We next asked whether knockdown of Dbr1 prevents TDP-43 toxicity in primary neurons. We showed previously that overexpression of TDP-43 in primary cortical neurons induces neurodegeneration with cytoplasmic mislocalization and aggregation of TDP-43, recapitulating several key pathological features of TDP-43 proteinopathies in vitro 28 . To determine whether Dbr1 knockdown protects neurons from TDP-43 cytotoxicity, we used automated microscopy and longitudinal analysis, a technique that identifies and characterizes variables that significantly contribute to neuronal survival 29 . We isolated and cultured rat primary cortical neurons and transfected them with three constructs expressing (i) mApple, (ii) enhanced green fluorescent protein (EGFP) or TDP-43 fused to EGFP (TDP-43-EGFP) and (iii) siRNA directed against Dbr1 or scrambled siRNA. With automated microscopy, hundreds of individual neurons were imaged from each cohort at regular 24-h intervals for 8 d (Fig. 3a) . In this experiment, mApple serves as a sensitive survival marker, as the loss of mApple fluorescence, cell blebbing or disruption of the cell membrane signifies cell death 29 . These criteria are at least as specific as those used with traditional markers of particular cell death pathways but have the advantage of detecting all forms of cell death in a single assay, thereby rendering them more sensitive. Because each neuron in a population can be followed longitudinally for an extended period of time, the analysis is analogous to that used in a prospective clinical trial. Powerful statistical tools developed for human epidemiological studies, including Kaplan-Meier survival analysis and Cox proportional hazards analysis, are used to describe the data that are generated from these experiments. We initially performed a small pilot experiment to determine the optimal amount of Dbr1 siRNA (Supplementary Fig. 3 ) and found that the most effective dose was 30 nM. On the basis of the effect size that we noted in the pilot experiment, the population sizes of subsequent experiments were scaled to achieve the power necessary to detect a significant effect on neuronal survival. As expected, the risk of death in primary cortical neurons was significantly greater in neurons expressing TDP-43-EGFP than in control neurons expressing EGFP alone (Fig. 3b) . The relative risk or hazard ratio calculated by Cox proportional hazards analysis was 2.23 (P < 1 × 10 −9 ), signifying an approximately twofold increase in the risk of death. Knockdown of Dbr1 in neurons expressing TDP-43-EGFP reduced the risk of death by nearly 20%, with a hazards ratio of 0.81 (P = 0.04). In contrast, knocking down Dbr1 had no effect on the survival of the control cohort expressing EGFP alone (hazards ratio 1.2, P = 0.3). Using a Kaplan-Meier survival curve to display the same data revealed a similar effect on neuron survival (Fig. 3c) . Notably, the improvement in survival mediated by Dbr1 knockdown did not depend on decreased amounts of cytoplasmic TDP-43. In fact, we observed significantly more primary neurons with cytoplasmic TDP-43 when treated with Dbr1 siRNA than with control siRNA (Fig. 3d) . These data suggest that neurons can survive even in the presence of cytoplasmic TDP-43. These results in primary neurons expressing human TDP-43 extend the protective effect of Dbr1 knockdown that we observed in yeast and in neuroblastoma cells and indicate that the ability of Dbr1 inhibition to suppress the toxic effects of TDP-43 accumulation is conserved from yeast to mammalian cells, organisms separated by a billion years of evolutionary divergence.
Dbr1 enzymatic activity is required for TDP-43 toxicity
DBR1 encodes an RNA debranching enzyme, highly conserved from yeast to man, that cleaves the 2′-5′ phosphodiester bonds of lariat introns that are formed during pre-mRNA splicing 30, 31 (Fig. 1c) . After transcription, primary pre-mRNA transcripts are processed by the spliceosome to remove introns, which are released as lariats 32 . Lariats are formed during splicing when the 5′ exon attacks the 3′ splice site in a nucleophilic manner. RNA nucleases within the cell can digest the 3′ tail of the lariat introns, but the lariat structure is resistant to digestion until Dbr1, a specialized debranching enzyme, cleaves the 2′-hydroxyl-5′-phosphate bond (Fig. 1c) . Debranching seems to be a rate-limiting step for the turnover of intronic RNA, as the steady-state levels of lariat introns are greatly increased in dbr1∆ cells 31, 33 .
Depletion of Dbr1 reduced TDP-43 toxicity in yeast (Fig. 1) , mammalian cells (Fig. 2) and primary neurons (Fig. 3) , but it was unclear whether the rescue was because of loss of debranching enzymatic activity or was potentially related to another Dbr1 function. To test this directly, we used 'debranching activity-dead' mutants of Dbr1. We cotransformed dbr1∆ yeast cells with expression plasmids for human TDP-43 and either wild-type yeast Dbr1 or two independent Dbr1 point mutants (Asp40Ala or Asn85Ala) that lack debranching enzymatic activity in vitro and in vivo 33 . Immunoblotting confirmed that the wild-type and mutant Dbr1 proteins were expressed at equivalent levels (Fig. 4a) . Whereas expressing wild-type Dbr1 restored TDP-43 toxicity to dbr1∆ cells, expressing either of the debranching-inactive Dbr1 point mutants did not (Fig. 4b) . Moreover, we tested a panel of 16 Dbr1 mutants, including some that retain full debranching activity, some that have lost all activity and some with partial debranching activity 33 . There was an exact correlation between debranching activity and the ability to restore TDP-43 toxicity to dbr1∆ cells: wild-type Dbr1 fully restored TDP-43 toxicity, whereas completely inactive Dbr1 had no effect, and partially active Dbr1 partially restored TDP-43 toxicity (Supplementary Table 1) . Thus, inhibiting Dbr1 debranching enzymatic activity is sufficient to rescue TDP-43 toxicity in yeast cells. Finally, expressing mouse Dbr1 in dbr1∆ cells was also sufficient to restore TDP-43 toxicity (Fig. 4b) , indicating that the debranching function of Dbr1 is conserved from yeast to mammals.
Lariat intron accumulation suppresses TDP-43 toxicity
In the absence of Dbr1, steady-state levels of lariat introns are greatly increased 33 . This suggested the intriguing possibility that the accumulating lariat introns in dbr1∆ cells could act as a kind of decoy for TDP-43, sequestering it away from important cellular RNAs and other RNA-binding proteins. To test this, we first determined whether the rescue of TDP-43 toxicity was specific to lariat intron accumulation or if accumulation of any nonspecific RNA species rescued toxicity. We expressed TDP-43 in three other yeast deletion strains (upf1∆, upf2∆ and xrn1∆) that each result in accumulation of RNA species within the cell, owing to alterations in the nonsense-mediated mRNA decay (NMD) pathway [34] [35] [36] [37] [38] . Whereas deleting DBR1 rescued (n = 380 neurons counted) significantly increases the risk of death over that of neurons expressing EGFP alone (n = 245 neurons counted; hazards ratio = 2.2). Knockdown of Dbr1 using 30 nM Dbr1 siRNA in neurons expressing TDP-43-EGFP (n = 300 neurons counted) decreases the risk of death by 19% compared to neurons expressing TDP-43-EGFP that received scrambled siRNA (n = 380 neurons counted). Data were pooled from two independent experiments, and statistical significance was determined using Cox proportional hazards analysis. ***, hazards ratio = 2.23 and P < 1 × 10 −9 ; **, hazards ratio = 1.83 and P < 1 × 10 −4 ; *, hazards ratio = 0.81 and P = 0.04. A r t i c l e s TDP-43 toxicity, TDP-43 toxicity was not suppressed in upf1∆, upf2∆ or xrn1∆ cells and was even slightly enhanced in upf1∆ and upf2∆ cells (Fig. 4c) , suggesting that the rescue of TDP-43 toxicity is specific to intronic lariat accumulation.
Intronic lariats suppress TDP-43 toxicity in the cytoplasm
We next sought to determine the mechanism by which intronic lariats suppress TDP-43 toxicity in dbr1∆ cells. We and others have shown that TDP-43 is toxic in the cytoplasm in multiple cellular and animal model systems 19, 28, 39, 40 . Thus, we reasoned that intronic lariats might accumulate in the nucleus of dbr1∆ cells, sequester TDP-43 there and prevent it from aggregating in the cytoplasm, thereby suppressing toxicity. In this model, sequestering TDP-43 in the cytoplasm should overcome the toxicity suppression by dbr1∆. To test whether this was the case, we retained TDP-43 in the cytoplasm by mutating its nuclear localization signal (NLS) 22, 41 . We reasoned that, if dbr1∆ suppresses TDP-43 toxicity in the nucleus, the TDP-43 mutant lacking an NLS would still be toxic. Unexpectedly, DBR1 deletion still suppressed toxicity when TDP-43 was sequestered in the cytoplasm (Fig. 5a) , suggesting that the site of action of intronic lariats is the cytoplasm.
The above genetic result suggested that intronic lariats act in the cytoplasm to suppress TDP-43 toxicity. To test this idea directly, we developed a method to visualize in living cells the endogenous intronic lariats that accumulate in dbr1∆ cells. We reasoned that, if we could visualize the intronic lariats, we could determine (i) whether they localized to the cytoplasm or nucleus and (ii) whether they colocalized with TDP-43 inclusions. A technique to visualize the localization of endogenous mRNAs in living yeast cells was recently developed 42 . m-TAG uses homologous recombination to insert binding sites for the RNA-binding MS2 coat protein (MS2-CP) between the coding region and 3′ UTR of any yeast gene. Expression of MS2-CP fused to GFP enables the visualization of any yeast mRNA that has been tagged with MS2-binding sites [42] [43] [44] . We modified m-TAG to visualize intronic lariats. Instead of tagging the 3′ UTR of a target yeast gene, we used homologous recombination to integrate MS2-binding sites in the intron of the ACT1 gene (Fig. 5b) , which has previously been shown by RNA blot analysis to accumulate in the absence of Dbr1 activity 33 .
We transformed wild-type and dbr1∆ yeast cells, each harboring MS2-binding sites integrated in the intron of the ACT1 gene (Fig. 5c) , with a plasmid containing a 3× GFP-tagged MS2-CP RNA-binding protein under control of the inducible MET25 promoter. We analyzed the localization of MS2-CP-GFP by fluorescence microscopy. As reported 43 , because the MET25 promoter is somewhat leaky, we detected the GFP fusion protein even without induction (by growth in the presence of methionine). In wild-type cells, in which no intronic lariats should accumulate 33 , we detected faint MS2-CP-GFP expression in a diffuse pattern throughout the cell (Fig. 5c and Supplementary Fig. 4) . In contrast, in dbr1∆ cells, MS2-CP-GFP accumulated in one or two bright foci per cell, and these were always located in the cytoplasm (Fig. 5c) . We observed similar results by tagging an independent intron from another yeast gene, CYH2 (data not shown). These foci could represent the excised lariat introns that accumulate in dbr1∆ cells or a splicing intermediate 45 ( Supplementary  Fig. 5 and Supplementary Note). However, as we did not see them in wild-type cells in which ACT1 or CYH2 introns were tagged with MS2-binding sequences ( Fig. 5c and Supplementary Fig. 4 ), these foci are likely to be lariat introns that accumulate in the absence of Dbr1 activity.
Intronic lariats colocalize with TDP-43 cytoplasmic foci in yeast
Having established that intronic lariats accumulate in the cytoplasm of dbr1∆ cells, we next tested our hypothesis that the accumulating lariats in dbr1∆ cells act as a decoy for TDP-43 by preventing it from interacting with other important cellular RNAs and RNA-binding proteins. We expressed untagged TDP-43 in wild-type and dbr1∆ cells and visualized its localization by immunocytochemistry with a TDP-43-specific antibody (Fig. 5d,e) . We visualized tagged intronic lariats by fluorescence microscopy. Notably, in every dbr1∆ cell analyzed, TDP-43 colocalized with intronic lariats (Fig. 5e) . Consistent with our genetic results (Fig. 5a ) and fluorescence microscopy experiments (Fig. 5c) , TDP-43 was not retained in the nucleus in dbr1∆ cells and accumulated in the cytoplasm (Fig. 5e) . However, the size and shape of TDP-43 inclusions were profoundly different in wild-type and dbr1∆ cells. In wild-type cells, TDP-43 formed multiple small, irregularly shaped cytoplasmic foci (Fig. 5d) , whereas in dbr1∆ cells, TDP-43 always formed at least one large, perfectly round focus (Fig. 5d) , which always colocalized with intronic lariats (Fig. 5e) . 
A r t i c l e s
Intronic lariats compete with RNAs for binding to TDP-43
We also assessed whether the TDP-43 ribonucleoprotein complex contains lariats. We expressed Flag-tagged TDP-43 in wild-type and dbr1∆ cells and immunoprecipitated TDP-43 from cell lysates with an antibody to Flag. The associated RNA was separated by twodimensional electrophoresis. Linear RNA molecules migrate in a diagonal on two-dimensional gels, but lariat and lariat breakdown products migrate in a separate arc, owing to the reduced mobility conferred by their altered structures (Supplementary Fig. 6a ). As expected, in wild-type and dbr1∆ cells, TDP-43 associated with RNA. However, in dbr1∆ cells, the TDP-43 ribonucleoprotein complex contained additional RNA species, consistent with intronic lariats.
Finally, to directly test our hypothesis that the intronic lariats that form in dbr1∆ cells act as decoys for TDP-43 by competing with it for binding to other cellular RNAs, we performed in vitro electrophoretic mobility shift assays. Incubation of a radioactively labeled RNA probe known to bind TDP-43 (ref. 46 ) with recombinant TDP-43 results in a gel shift (Supplementary Fig. 6b,c) . We isolated total RNA from wildtype and dbr1∆ cells and tested the ability of these RNAs to compete for binding to TDP-43. As expected, RNAs from wild-type and dbr1∆ cells competed for TDP-43 binding (Supplementary Fig. 6b) , consistent with TDP-43 binding a large number of RNA targets 47 . To specifically test the ability of intronic lariats to compete for binding to TDP-43 (to act as decoys), we treated RNAs isolated from wild-type and dbr1∆ cells with RNase R, which degrades all RNAs except for branched lariats 48 . When these RNase R-treated samples were incubated with the TDP-43 binding reaction, only the RNase R-treated RNAs isolated from dbr1∆ cells competed TDP-43 away from its binding site ( Supplementary  Fig. 6c) . Thus, dbr1∆ cells contain an RNase R-resistant species, likely intronic lariats, that compete for binding to TDP-43.
DISCUSSION
Using two unbiased genetic screens in yeast, we discovered Dbr1 as a potent modifier of TDP-43 toxicity. We provide evidence that, in the absence of Dbr1, intronic lariats accumulate in the cytoplasm, and we propose that these act as decoys to sequester TDP-43, preventing it from interfering with essential RNAs and RNA-binding proteins. Thus, we suggest that the debranching enzymatic activity of Dbr1 could be a novel therapeutic target to combat toxic effects from cytoplasmic TDP-43 aggregation in ALS. The additional genetic modifiers of TDP-43 toxicity uncovered from these two yeast screens (Table 1 and Supplementary Data) will hopefully provide even more insight into disease mechanisms and open new avenues for therapeutic intervention.
Recent studies indicate that RNA binding is an important component of TDP-43 toxicity in cellular and animal models 19, 22, 49, 50 . One potential mechanism of neurotoxicity is that TDP-43 aggregates in the cytoplasm, sequestering essential cellular RNAs and RNA-binding npg proteins away from their normal functions. This could lead to catastrophic changes in RNA metabolism, owing to defects in the stability, splicing, transport and/or translation of essential RNAs. This effect might be more deleterious to motor neurons if motor neuronspecific transcripts were preferentially sequestered by TDP-43 or even if motor neurons were simply more sensitive to subtle alterations in any of these RNA metabolic pathways. TDP-43 loss of function likely also contributes to disease. TDP-43 is depleted from the nuclei of affected neuronal populations in individuals with ALS 8 , and downregulation of TDP-43 in mouse leads to widespread dysregulation of splicing 47 . Finally, TDP-43 missense variants might act in a dominant-negative manner, interfering with the function of the wild-type protein 51, 52 . These three pathogenic mechanisms (gain of toxic properties in the cytoplasm, loss of function in the nucleus and dominant-negative effects) are not mutually exclusive and likely all contribute to ALS pathogenesis.
Inhibiting Dbr1 function might overcome or prevent cytoplasmic TDP-43 (and FUS) aggregates from disrupting critical RNAs and RNA-binding proteins. We propose that the accumulated intronic lariat species in dbr1∆ cells suppress TDP-43 toxicity by acting as decoys, causing TDP-43 to bind to them rather than to important cellular RNA targets (Fig. 5f) . The catalog of genome-wide RNA targets for TDP-43 is emerging 47, [53] [54] [55] . Notably, TDP-43 seems to preferentially bind to long intronic pre-mRNA sites rather than coding exonic regions or UTRs 47 . This might explain why the intronic RNA sequences (lariats) that accumulate in dbr1∆ cells sequester TDP-43 away from other RNA species in the cell and suppress TDP-43 toxicity. TDP-43 might also preferentially recognize the lariat branch-point structure, or binding to the lariat might promote nucleation or other alterations to TDP-43 conformation.
For Dbr1 to be a therapeutic target, several questions must be addressed. First, could inhibition of Dbr1 debranching activity be toxic itself? Indeed, the highest concentration of Dbr1 siRNA (50 nM) in primary rat neurons increased the risk of death ( Supplementary  Fig. 3 ), suggesting that too much Dbr1 inhibition could be deleterious. However, in budding yeast, DBR1 deletion is tolerated (Fig. 1a) , and siRNA knockdown in M17 cells does not result in growth inhibition (ref. 56 and M.A. and A.D.G., unpublished data). Nevertheless, it will be important to determine what level of Dbr1 inhibition is tolerated and whether an appropriate therapeutic index can be achieved. An additional consideration for this approach in mammalian cells is the non-coding RNAs in intronic regions that depend on Dbr1 activity. Expression of these non-coding RNAs might be dysregulated by Dbr1 inhibition, and the consequences of this must be assessed. Furthermore, as abnormal accumulation of RNA is hypothesized to trigger autoimmunity and there would likely be a large pool of lariats in human cells, the effects of Dbr1 inhibition on autoimmunity should be analyzed. Although, to our knowledge, Dbr1 inhibitors are not available, our new method to visualize intronic lariats in living cells (Fig. 4) will facilitate screening of chemical compound libraries for small molecule Dbr1 inhibitors.
There are currently no TDP-43-directed therapies for ALS or related TDP-43 proteinopathies. Antisense oligonucleotides and RNA interference approaches are emerging as attractive therapeutic strategies in neurodegenerative diseases in which decreasing levels of a toxic mutant protein might be efficacious [57] [58] [59] [60] . Indeed, treating a mouse model of inherited ALS (caused by a mutation in SOD1) with antisense oligonucleotides to SOD1 significantly slowed disease progression 4 . This approach offers tremendous promise for treating patients with ALS with SOD1 mutations, but, as mutations in SOD1 account for only ~2-5% of all ALS cases, additional therapeutic strategies are needed. Because TDP-43 appears to contribute to ALS pathogenesis broadly 7 , targeting TDP-43 with antisense approaches could be effective. However, it is unknown whether TDP-43 contributes to disease via loss-or gain-of-function mechanisms 61 , mandating caution in pursuing TDP-43-lowering approaches. We present an alternative strategy: by targeting Dbr1 using small molecule inhibitors or antisense oligonucleotides, it might be possible to antagonize the toxic effects of TDP-43 in the cytoplasm without interfering with potentially critical functions in the nucleus.
URLs. Study protocols, http://www.gladstone.ucsf.edu/gladstone/ site/finkbeiner/.
METHODS
Methods and any associated references are available in the online version of the paper. 62 and Htt103Q expression plasmids were as described 63 . The yeast Dbr1 mutant expression plasmids 33 and m-TAG plasmids pLOXHIS5MS2L, pSH47 and pMS2-CP-GFP (×3) were as described 44 .
ONLINE METHODS
Yeast TDP-43 toxicity modifier screens. We used the SGA technique to screen the collection of nonessential-only yeast knockout strains (screen 1, performed in the laboratory of A.D.G.) or a collection of nonessential yeast knockout strains combined with essential genes reduced in expression by DAmP 27 (screen 2, performed in the laboratories of R.V.F. and N.K.) for modifiers of TDP-43 toxicity. These screens were performed as described 26, 64, 65 , with some modifications 66 , using a Singer RoToR HDA (Singer Instruments). For screen 1, the galactose-inducible TDP-43 expression construct (pAG416Gal-TDP-43) was introduced into MATα strain Y7092 to generate the query strain. This query strain was mated to the yeast haploid deletion collection of nonessential genes (MATα, each gene deleted by KanMX cassette; Fig. 1a) . Haploid mutants harboring the TDP-43 expression plasmid were grown in the presence of glucose (TDP-43 expression off) or galactose (TDP-43 expression on). After growth at 30 °C for 2 d, plates were photographed, and colony sizes were measured by ImageJ image analysis software as described 67 . The entire screen was repeated three times, and only hits that were reproduced all three times were selected for further validation by random spore analysis on DNA sequencing of deletion strain barcodes.
For screen 2, a control query strain containing the empty vector was generated by transforming the yeast strain BY5563 (Matα) with p415-Gal-GFP, and the experimental query strain was generated by transforming BY5563 (Matα) with p415-Gal-TDP-43-GFP. Both strains were mated with the combined yeast knockout DAmP collection (Matα). Haploid yeast containing the deletion/DAmP yeast gene with the control or experiment plasmid were selected as described 65 . Three biological replicates were isolated by selecting for haploid yeast after sporulation on three plates. Each biological replicate was duplicated to generate six replicates (three biological and two technical replicates per biological replicate). Plates were imaged at several time points after final inoculation on glucose or galactose. Colony size was assessed as described 67 .
Isolation and culturing of primary cortical neurons. Rat cortical neurons were isolated from embryonic day 20-21 rat (Sprague Dawley) pups, cultured in serum-free medium in 96-well plates for 4 d in vitro and then transfected using Lipofectamine 2000 (Invitrogen; see URLs for full protocols). Neurons were transfected with plasmids (pGW1 backbone) encoding mApple and either TDP-43-EGFP or EGFP and with siRNA directed against Dbr1 (SMARTpool, Dharmacon) or scrambled siRNA (Dharmacon).
Live-cell imaging for longitudinal analysis.
For neuronal survival analysis, we used a robotic imaging system as described 68, 69 . Briefly, approximately 24-48 h after transfection, images were acquired with an inverted Nikon microscope (TE2000) equipped with PerfectFocus, an extra-long working distance (ELWD) 20× objective lens and an Andor Clara 16-bit, ultra-cooled camera. Illumination was provided by an adjustable, high-intensity and long-lasting xenon lamp, and a liquid light guide was used to maximize the signal-to-noise ratio. The stage and shutter movements, fluorescence excitation and emission filters, focusing and image acquisition were fully automated and were controlled through a 64-bit host computer running a combination of proprietary software (ImagePro, Media Cybernetics) and custom-designed algorithms.
Survival analysis. Digitized images from the red fluorescent protein (RFP; mApple) and green fluorescent protein (GFP; TDP-43-EGFP) channels were assembled into montages with ImagePro, and cells were prospectively counted in the RFP channel by original code developed in Matlab. Cell death was marked by loss of fluorescence, membrane rupture or neurite retraction. The time of death for each neuron was defined as the last time the neuron was seen. Kaplan-Meier and cumulative risk of death curves were generated using the survival package in R. Statistical significance of survival differences between cohorts of neurons was determined by the log-rank test, and Cox proportional hazards analysis was used to measure the relative change in the risk of death, the hazard ratio. Two-dimensional nucleic acid gels. Nucleic acid pellets from immunoprecipitation were resuspended in 5 µl of nuclease-free water and 5 µl of 2× nucleic acid loading dye (0.025 g xylene cyanol and 0.025 g bromophenol blue in 100% formamide) and were heated at 85 °C for 5 min. Nucleic acids were separated in the first dimension by loading samples into a prerun (300 V for 10 min) 5% polyacrylamide gel (19:1 acrylamide:bis-acrylamide) containing 7 M urea and 1× TBE (90 mM Tris base, 90 mM boric acid, 2 mM EDTA, pH 8.0) and electrophoresing them at 300 V. Nucleic acids were separated in the second dimension by placing the entire lane from the first-dimension gel above the second-dimension gel. The second-dimension gel was exactly the same as the first-dimension gel, except that it contained 10% polyacrylamide. Samples were electrophoresed at 300 V until xylene cyanol dye reached the bottom of the second-dimension gel. Two-dimensional nucleic acid gels were washed briefly in water and then placed in 1× SYBR Gold (Invitrogen) solution prepared in water. Gels were protected from light and gently agitated at 23-25 °C in 1× SYBR Gold solution for 45 min. Images of the gels were captured on an ultraviolet light box at an excitation wavelength of 302 nm with a 4-s exposure time.
Genomic tagging strategy to visualize intronic lariats. To visualize intronic lariats in dbr1∆ cells, we adapted the m-TAG protocol 42 for use with introns. We used PCR-based chromosomal gene tagging, using homologous recombination to integrate the loxPøSphis5 + øloxPøMS2L cassette into the intron of either the ACT1 gene or the CYH2 gene in wild-type or dbr1∆ cells. For ACT1, we inserted the MS2L cassette at nucleotide 159 of the ACT1 genomic DNA sequence (ACT1/YFL039C on chromosome VI from coordinates 54,696 to 53,260). For CYH2, we inserted the MS2L cassette at nucleotide 303 of the CYH2 genomic DNA sequence (RPL28/YGL103W on chromosome VII from coordinates 310,967 to 311,927). To excise the loxP-flanked Sphis5 cassette, we transformed cells with plasmid pSH47, which expresses Cre recombinase under control of a galactose-regulated promoter. Proper integration of MS2L sequences was verified by colony PCR and DNA sequencing.
Visualizing tagged intronic lariats by fluorescence microscopy. We visualized MS2L-tagged intronic lariats in wild-type and dbr1∆ cells as described 42 . We transformed wild-type and dbr1∆ cells harboring an MS2L-tagged ACT1 intron with pMS2-CP-GFP(×3), which expresses MS2-CP fused to three copies of GFP under the control of the MET25 promoter. Yeast cells were fixed with 70% ethanol and stained with DAPI in Vectashield mounting medium. Colocalization of an MS2L-tagged intronic lariat with TDP-43 was determined using fluorescence microscopy to detect lariats (GFP) and immunocytochemistry with a TDP-43-specific antibody to detect untagged TDP-43.
TDP-43 lentiviruses.
To generate a lentiviral vector for the conditional expression of TDP-43 Gln331Lys, a Gateway entry clone encoding N-terminally Flag-tagged and C-terminally Myc-tagged TDP-43 Gln331Lys was used in a Gateway LR reaction (Invitrogen) to transfer it to the pSLIKNeo lentiviral destination vector. Recombinant lentiviruses were produced as described 70 . For lentiviral transduction, human M17 neuroblastoma cells (ATCC) were incubated with lentiviral supernatants for 6 h at 37 °C. Stable cell lines were selected by culturing transduced cells for 5 d in growth medium (minimum essential medium (MEM) alpha/F-12 (Invitrogen) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin (complete medium) with 100 µg/ml Geneticin). Individual clones were selected and analyzed for inducible expression by immunoblotting and immunofluorescence analyses.
TDP-43 toxicity assays in mammalian cells.
We assessed the effect of TDP-43 on cell proliferation in the MTT assay. M17 cells stably transduced with either an empty vector or with the vector encoding TDP-43 Gln331Lys were seeded in 96-well plates. To induce TDP-43 Gln331Lys expression, doxycycline (0.1, 1 or 2 µg/ml) was added to the growth medium, and cells were incubated npg for 3 d. To measure proliferation, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well, and cells were incubated for 4 h at 37 °C. Acidic isopropanol (40 mM HCl) was then added to each well to solubilize the blue formazan crystals. Absorbance at 570 nm was read with a Tecan Safire II plate reader. Absorbance measurements were normalized to the absorbance of cells not treated with doxycycline and used to calculate the percent viability under each condition. Two-way ANOVA was used to evaluate differences in means between two groups, and P values of <0.05 were considered statistically significant. Each condition was replicated at least four times, and each experiment was independently repeated at least three times.
siRNA knockdown of DBR1 in M17 cells. siRNA targeting human DBR1 and non-targeting control siRNA were purchased from Thermo-Scientific (DBR1, J-008290-08-0005; non-targeting, D-001810-01-05). siRNA knockdown was validated by immunoblotting with a Dbr1-specific antibody (Proteintech, rabbit polyclonal antibody, 16019-1-AP). The M17 cell line with inducible TDP-43 Gln331Lys expression was transfected with 50 nM human DBR1 siRNA or non-targeting control siRNA using RNAi Lipofectamine (Invitrogen). After 2 d, cells were transferred to medium containing doxycycline (0 and 1 µg/ml) to induce expression of TDP-43, and toxicity was then assessed by MTT assay after 2 d (on day 4 after transfection). TDP-43 toxicity in M17 cells transfected with DBR1 siRNA was compared to toxicity in cells transfected with nontargeting control siRNA or empty vector.
TDP-43 in vitro RNA-binding assay. Glutathione S-transferase (GST)-TDP-43 was purified from Escherichia coli as described 20 . RNA binding assays were performed as described 71 . Briefly, competitor RNA was purified from wild-type or dbr1∆ W303 yeast using the RNeasy Mini kit (Qiagen) and was either left untreated or was treated with RNase R to degrade any linear RNA structures while leaving lariat RNA intact. After RNase R treatment, RNA was purified using the RNeasy MinElute Cleanup kit (Qiagen). A radioactively labeled RNA probe, UG 6 , which is known to bind TDP-43 (ref. 46) , was generated by T7 polymerase-catalyzed transcription of a DNA template in the presence of [ 32 P]-labeled UTP. Standard binding reactions were carried out in a 10-µl volume containing 4 mM MgCl 2 , 25 mM phosphocreatine, 1.25 mM ATP, 1.3% polyvinyl alcohol, 25 ng of yeast tRNA, 0.8 mg of BSA, 1 mM DTT, 0.1 µl Rnasin (Promega, 40 U/ml), 75 mM KCl, 10 mM Tris, pH 7.5, 0.1 mM EDTA and 10% glycerol. Binding reactions containing GST-TDP-43 (0.5 µM) and [ 32 P]-labeled UG 6 (1 µl) were incubated for 15 min at 30 °C in the presence of various dilutions of competitor RNA (0-12.9 µg). Binding reactions were then transferred to ice, and heparin was added to a final concentration of 0.5 µg/µl. Reactions were analyzed on a 4.5% native gel (acrylamide:bis-acrylamide (29:1), Bio-Rad).
